Dr. Khayrallah is a serial entrepreneur and investor in pharmaceutical drug development and biotechnology. He acquired his experience over a 40-year period in diverse pharmaceutical environments including large pharmaceutical, contract research, and biotechnology companies. His latest startup venture is Emergo Therapeutics Inc. that develops drugs to modulate inflammatory cytokines and improve the functioning of the immune system in infectious disease indications. Emergo is his fifth startup biopharmaceutical company. He is also Chairman of the Board and co-Founder of QuatroBio, LLC, a startup biopharmaceutical holding company focused on developing drugs for central nervous system disorders. He is also currently on the Board of Directors of several startup companies in the pharmaceutical or information technology industries. Prior to these current positions, Dr. Khayrallah co-founded and led Aerial BioPharma, LLC, which sold its major drug asset, Sunosi (solriamfetol), to Jazz Pharmaceuticals in early 2014. In 2010, Dr. Khayrallah was co-founder, President and CEO of Neuronex Inc., a company focused on developing treatments for patients with certain seizure disorders.  Neuronex was acquired by Acorda Therapeutics in 2013. In 2006, he co-founded and served as President and CEO of Addrenex Pharmaceuticals, Inc., a specialty pharmaceuticals company that developed and received FDA approvals for compounds targeting the adrenergic system. Addrenex was acquired in late 2009 by Shionogi & Co. of Japan. In 2002, Dr. Khayrallah founded a consulting company, Alius Pharma, LLC, to partner with small biotechnology companies in cancer drug development. From 1999 to 2002, he was VP of Clinical Affairs at Cytran, Inc., a Seattle area biotechnology company, where he led the product development team for the company’s lead compound in cancer and participated in financing and joint venture activities. Prior to that, Dr. Khayrallah served as Director, Clinical Research and Regulatory Affairs at Lineberry Research Associates (later Constella Group and SRI International) in RTP, NC. While at Lineberry, he led project teams in implementing clinical projects and providing strategic consulting in several therapeutic areas. Dr. Khayrallah also served in various positions at Burroughs Wellcome Co. and later Glaxo Wellcome (now GlaxoSmithKline) from 1987 to 1996, where he led trials and clinical programs resulting in FDA approvals in CNS indications. He holds a Ph.D. degree in psychology from the University of North Carolina at Chapel Hill and a Bachelor's degree in psychology from the American University of Beirut.

Dr. Khayrallah is also actively involved with the entrepreneurial and non-profit networks in the United States and beyond.  He currently serves as the Honorary Consul for Lebanon in NC, a position that allows him to assist the Lebanese American community and represent its interests in Lebanon and the US.  He is the Founder and Board Chair of Lebanon & Beyond (L&B), a non-profit organization that seeks to revitalize Lebanon and its worldwide diaspora through innovative educational programs that strengthen connections between the diaspora and the ancestral land.  With offices and staff in the US and Lebanon, L&B currently runs two programs: Jouzour, an immersive summer program that returns young people from the Lebanese diaspora to Lebanon for cultural education, hands-on service, and building enduring connections; and Jana, a multi-year program that partners with visionary educators in Lebanon and beyond to collectively shape the future of equitable schooling in Lebanon in an era defined by artificial intelligence and rapid digital transformation.  In 2014, he endowed the Moise A. Khayrallah Center for Lebanese Diaspora Studies at North Carolina State University, the first center of its kind outside of Lebanon.  The Center is the first privately endowed center in NC State’s history and the largest gift to the College of Humanities and Social Sciences.  The Center seeks to preserve, research, and document the history of the worldwide Lebanese diaspora through an online archive, documentaries and exhibitions, lectures and talks, and the annual Khayrallah Prize that honors original literary and artistic works focused on the diaspora experience inside or outside Lebanon.  Dr. Khayrallah is a current or recent member of several Boards and advisory committees including: Member, Board of Trustees of the Lebanese American University (LAU), where he assists the Board and university administration in the fields of healthcare sciences and entrepreneurship; Member, International Advisory Council of the American University of Beirut (AUB) where he works on educational and entrepreneurship initiatives; Former Member, Board of Directors of the North Carolina Biotechnology Center; Former Chair, Board of Directors of Carolina Ballet; Former Chair, Board of Directors of Go Global NC; Former Member, Blackstone Entrepreneurs network; Former Member, UNC-Chapel Hill Chancellor’s Philanthropic Council responsible for fundraising for the UNC Campaign for Carolina; and Former Member, UNC School of Education Board of Visitors.  At the UNC School of Education, he created the Moise A. Khayrallah Innovation Fund that supports the Master of Arts in Educational Innovation, Technology and Entrepreneurship (MEITE) program.  Dr. Khayrallah also seeks to assist multicultural and global programs in their efforts to bring people together and highlight cultural commonalities.  He supports educational, cultural, and artistic organizations, as well as charitable organizations in the US and overseas.